Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Open Access
- 1 March 2002
- Vol. 50 (3), 425-427
- https://doi.org/10.1136/gut.50.3.425
Abstract
Chronic hepatitis C is a major healthcare problem. The response to antiviral therapy for patients with chronic hepatitis C has previously been defined biochemically and by PCR. However, changes in the hepatic venous pressure gradient (HVPG) may be considered as an adjunctive end point for the therapeutic evaluation of antiviral therapy in chronic hepatitis C. It is a validated technique which is safe, well tolerated, well established, and reproducible. Serial HVPG measurements may be the best way to evaluate response to therapy in chronic hepatitis C.Keywords
This publication has 37 references indexed in Scilit:
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Hepatitis C: The clinical spectrum of diseaseHepatology, 1997
- Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis CHepatology, 1997
- Hepatic venous pressure measurement: An old test as a new prognostic marker in cirrhosis?Hepatology, 1997
- Liver cancer: Clinical/experimental treatment and carcinogenesisHepatology, 1995
- Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alphaJournal of Hepatology, 1995
- Correlations between sinusoidal pressure and liver morphology in cirrhosisJournal of Hepatology, 1994
- Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C: Effects on inflammation, fibrogenesis and viremiaJournal of Hepatology, 1993
- α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markersJournal of Hepatology, 1993
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991